While treatments for melanoma have been steadily improving over recent years, patients with brain metastases have consistently had poor outcomes. In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Melbourne, Australia, discusses recent developments in targeted therapy and immunotherapy, which might improve these patients prognoses. He outlines the biology of melanoma brain metastases that make these therapies possible: disruption of the blood-brain barrier and tumor infiltration of CD8 T-cells improves efficacy of targeted therapies and immune checkpoint therapies. Dr McArthur finally describes some recent trial data, which prove these concepts and show an increased median survival: a definite step in the right direction.
Recent developments in melanoma with brain metastases
